Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02386826 · ClinicalTrials.gov registry record · Phase 1
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
A Phase 1 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT02386826 is a Phase 1 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 65 participants.
The verdict
NCT02386826, a Phase 1 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of two agents, INC280 and bevacizumab, is safe and effective when administered to patients with Glioblastoma Multiforme (GBM) who have progressed after receiving prior therapy or who have unresectable GBM.
Interventions
- BIOLOGICAL bevacizumab
- DRUG INC280
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2015-09-22 |
| Est. Completion | 2023-08-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02386826
The ClinicalTrials.gov registry entry for NCT02386826 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT02386826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02386826 about?
NCT02386826 is a clinical study titled "INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme". The purpose of this study is to determine whether the combination of two agents, INC280 and bevacizumab, is safe and effective when administered to patients with Glioblastoma Multiforme (GBM) who have progressed after receiving prior therapy or who have unresectable GBM.
What is the current status of trial NCT02386826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2015-09-22. Estimated completion is 2023-08-23.
What interventions are being tested in trial NCT02386826?
The interventions under investigation include: bevacizumab (BIOLOGICAL), INC280 (DRUG).
Who is sponsoring clinical trial NCT02386826?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.